Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
| ▸ | PTPRF | P10586 | 1/20 | 0.38 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL102322 | 1.00 | KDM4E (0.42) | KDM4EHTTATMPTPRFPTPN1 | |
| SCHEMBL3809144 | 0.94 | KDM4E (0.40) | KDM4EHTTATMPTPRFPTPN1 | |
| SCHEMBL2157604 | 0.93 | HSD17B1 (0.39) | KDM4EMAPT | |
| SCHEMBL2157591 | 0.92 | KDM4E (0.42) | KDM4EHTTATMPTPRFPTPN1 | |
| SCHEMBL2876741 | 0.92 | POLB (0.41) | KDM4EHTTATMMAPT | |
| SCHEMBL14521764 | 0.90 | IKBKB (0.34) | KDM4EHTTATMPTPRFPTPN1 | |
| SCHEMBL2157715 | 0.90 | PTPN1 (0.41) | KDM4EPTPN1MAPT | |
| SCHEMBL4156123 | 0.90 | PTPN1 (0.41) | KDM4EPTPN1MAPT | |
| SCHEMBL2158018 | 0.90 | IKBKB (0.44) | KDM4EPTPN1MAPT | |
| SCHEMBL14042870 | 0.90 | IKBKB (0.34) | KDM4EHTTATMPTPRFPTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160206678-A1 | HCV COMBINATION THERAPY | BOEHRINGER INGELHEIM INT (DE) | 2016-07-21 | — | — | US | disclosed |
| US-20160206678-A1 | HCV COMBINATION THERAPY | BOEHRINGER INGELHEIM INT (DE) | 2016-07-21 | — | — | US | disclosed |
| US-20160031927-A1 | Alkyl 2--propionates, nucleoside inhibitors of HCV RNA-polymerase NS5B, methods for preparation and use thereof | IVACHTCHENKO ALEXANDRE VASILIEVICH (RU) | 2016-02-04 | — | — | US | disclosed |
| US-20160031927-A1 | Alkyl 2--propionates, nucleoside inhibitors of HCV RNA-polymerase NS5B, methods for preparation and use thereof | IVACHTCHENKO ALEXANDRE VASILIEVICH (RU) | 2016-02-04 | — | — | US | disclosed |
| US-20150164884-A1 | HCV COMBINATION THERAPY | BOEHRINGER INGELHEIM INT (DE) | 2015-06-18 | — | — | US | disclosed |
| US-20150164884-A1 | HCV COMBINATION THERAPY | BOEHRINGER INGELHEIM INT (DE) | 2015-06-18 | — | — | US | disclosed |
| US-20130029904-A1 | HCV COMBINATION THERAPY | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-01-31 | — | — | US | disclosed |
| US-20130029904-A1 | HCV COMBINATION THERAPY | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-01-31 | — | — | US | disclosed |
| US-8158779-B2 | Antiviral nucleosides | MEDIVIR AB (SE) | 2012-04-17 | — | — | US | disclosed |
| US-8158779-B2 | Antiviral nucleosides | MEDIVIR AB (SE) | 2012-04-17 | — | — | US | disclosed |
| US-20090136448-A1 | Antiviral 2-Carboxy-Thiophene Compounds | CORFIELD JOHN ANDREW | 2009-05-28 | — | — | US | disclosed |
| US-20090136448-A1 | Antiviral 2-Carboxy-Thiophene Compounds | CORFIELD JOHN ANDREW | 2009-05-28 | — | — | US | disclosed |
| US-20090136448-A1 | Antiviral 2-Carboxy-Thiophene Compounds | CORFIELD JOHN ANDREW | 2009-05-28 | — | — | US | disclosed |
| US-7531534-B2 | Heterocyclic antiviral compounds | ROCHE PALO ALTO LLC (US) | 2009-05-12 | — | — | US | disclosed |
| US-7479489-B2 | Heterocyclic antiviral compounds | ROCHE PALO ALTO LLC (US) | 2009-01-20 | — | — | US | disclosed |
| WO-2009000818-A1 | 3-CARBONYLAMINOTHIOPHENE-2-CARBOXYLIC ACIDS AS HEPATITIS C VIRUS INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2008-12-31 | — | — | WO | disclosed |
| US-20080200512-A1 | Hepatitis C virus polymerase inhibitors | BLANEY JEFFREY MARK | 2008-08-21 | — | — | US | disclosed |
| US-20080152621-A1 | Antiviral nucleosides | ROCHE PALO ALTO LLC | 2008-06-26 | — | — | US | disclosed |
| US-20080095739-A1 | Heterocyclic antiviral compounds | ROCHE PALO ALTO LLC | 2008-04-24 | — | — | US | disclosed |
| WO-2007071434-A1 | ANTIVIRAL 2-CARBOXY-THIOPHENE COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2007-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080152621-A1 | Antiviral nucleosides | PNP, MTAP, UMPS | KDM4E 740/4885HTT 3651/4885ATM 3842/4885 |
| US-20080095739-A1 | Heterocyclic antiviral compounds | EIF2AK2, POLR2A, HCCS | KDM4E 2451/4885HTT 3112/4885ATM 3649/4885 |
| US-20080200512-A1 | Hepatitis C virus polymerase inhibitors | SSU72, POLR2H, POLR2E | KDM4E 2519/4885HTT 2341/4885ATM 4443/4885 |
| US-20150164884-A1 | HCV COMBINATION THERAPY | HAVCR2, ZC3HAV1, SLC10A1 | KDM4E 3998/4885HTT 3020/4885ATM 4498/4885 |
| US-20090136448-A1 | Antiviral 2-Carboxy-Thiophene Compounds | EIF2AK2, HAVCR2, MAVS | KDM4E 794/4885HTT 3552/4885ATM 4348/4885 |
| US-20160206678-A1 | HCV COMBINATION THERAPY | HAVCR2, ZC3HAV1, SLC10A1 | KDM4E 3998/4885HTT 3020/4885ATM 4498/4885 |
| US-20160031927-A1 | Alkyl 2--propionates, nucleoside inhibitors of HCV RNA-polymerase NS5B, methods for preparation and use thereof | RNGTT, NSUN2, MED1 | KDM4E 2842/4885HTT 2193/4885ATM 3790/4885 |
| US-20130029904-A1 | HCV COMBINATION THERAPY | HAVCR2, ZC3HAV1, SLC10A1 | KDM4E 3965/4885HTT 2583/4885ATM 4411/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.